COMBIVET
  • Home
    • About us
    • Combivet Ethics Committee
    • Contact
  • Team
  • Research
    • ​Host-Pathogen Interactions and Disease Biomarkers Discovery >
      • Research project I
      • Research project II
    • Infertility and Subfertility >
      • Research project III
      • Research project IV
      • Research project V
    • ​Food, Feed & Health >
      • Research project VI
    • Non - Communicable Diseases and Cancer >
      • Research project VII
      • Research project VIII
  • Publications
  • NEWS & EVENTS
    • News
    • Seminars
    • Events >
      • Annual conference 2024
      • Research school 2024
      • Ethics debate 2023
      • Research school 2023
      • Annual conference 2023
      • Symposium 2023
      • Conference 2022
      • Summer School 2022
      • One Health Estonia 2022
      • CANLEISH/COMBIVET joint event 2022
  • University of Life Sciences
  • EUP AH&W

Aija Linē 

Associate Professor, Faculty of Biology, University of Latvia, Riga, Latvia Group Leader, Latvian Biomdical Center, Riga, Latvia
Prof. Aija Linē is the head of Cancer Biomarker group, the scientific director of Latvian Biomedical Research and Study center and professor at University of Latvia in molecular genetics and immunology. She obtained her PhD at the University of Latvia in 2002 on the ​identification and characterization of tumor antigens recognized by B cells. During her PhD and post-doctoral studies she undertook several training periods at Nottingham Trent University to study the molecular alterations underlying their immunogenicity. In 2004 she established her group focusing on the discovery of circulating cancer biomarkers. Currently, her research interests are focused on the extracellular vesicles as a source of cancer biomarkers for liquid biopsies and therapeutic tools for the treatment of cancer. She has published 55 peer-reviewed article cited >10700 times, her H-index is 26 and she has been a speaker at >20 international conferences.


Comprehensive characterization of RNA cargo in EVs from a longitudinal

​cohort of breast cancer patients undergoing neoadjuvant chemotherapy 

Extracellular vesicles (EVs) are gaining increased attention as carriers of cancer-derived molecules for liquid biopsies. Here, we studied the dynamics of EV levels in the plasma of breast cancer (BC) patients undergoing neoadjuvant chemotherapy (NAC) and explored the relevance of their RNA cargo for the prediction of patients' response to the therapy. EVs were isolated from serial blood samples collected at the time of diagnosis, at the end of NAC, and 7 days, 6, and 12 months after the surgery from 32 patients with locally advanced BC, and 30 cancer-free healthy controls (HCs) and quantified by nanoparticle tracking analysis. The pre-treatment levels of EVs in BC patients were higher than in HCs, significantly increased during the NAC and surgery, and decreased to the levels found in HCs 6 months after surgery, thus showing that a substantial fraction of plasma EVs in BC patients are produced due to the disease processes and treatment. RNA sequencing analysis revealed that the changes in the EV levels were associated with the alterations in the proportions of various RNA biotypes in EVs. BC-derived biomarker candidates were identified among mRNAs, miRNAs, lncRNAs, snoRNAs, piRNAs, snRNAs, and tRFs. Several biomarker models for the detection and monitoring of BC and prediction of ​response to NAC were established. Furthermore, a number of RNAs that were induced by NAC in non-responders or patients with early disease progression were identified and warrant further functional studies on their role in chemo resistance and metastasis.

​COMBIVET

MENU
ADDRESS
Estonian University of Life Sciences
Institute of Veterinary Medicine and Animal Sciences

​
Picture
Home
Research
Publications
News & Events
University of Life Sciences
Kreutzwaldi 62,
Tartu 51006,
tel/fax 7313 706
​Estonia
Contact us
Picture
​This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 857418.
  • Home
    • About us
    • Combivet Ethics Committee
    • Contact
  • Team
  • Research
    • ​Host-Pathogen Interactions and Disease Biomarkers Discovery >
      • Research project I
      • Research project II
    • Infertility and Subfertility >
      • Research project III
      • Research project IV
      • Research project V
    • ​Food, Feed & Health >
      • Research project VI
    • Non - Communicable Diseases and Cancer >
      • Research project VII
      • Research project VIII
  • Publications
  • NEWS & EVENTS
    • News
    • Seminars
    • Events >
      • Annual conference 2024
      • Research school 2024
      • Ethics debate 2023
      • Research school 2023
      • Annual conference 2023
      • Symposium 2023
      • Conference 2022
      • Summer School 2022
      • One Health Estonia 2022
      • CANLEISH/COMBIVET joint event 2022
  • University of Life Sciences
  • EUP AH&W